Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression

Kazushige Wakuda,Michitoshi Yabe,Hiroaki Kodama,Naoya Nishioka,Taichi Miyawaki,Eriko Miyawaki,Nobuaki Mamesaya,Takahisa Kawamura,Haruki Kobayashi,Shota Omori,Akira Ono,Hirotsugu Kenmotsu,Tateaki Naito,Haruyasu Murakami,Hideyuki Harada,Masahiro Endo,Yasuhiro Gon,Toshiaki Takahashi

Lung Cancer（2021）

引用 17|浏览23

暂无评分

摘要

•Assessed the efficacy of pembrolizumab for brain metastasis of PD-L1 high NSCLC.•Survival did not significantly differ in patients with and without brain metastasis.•Response rate of brain metastasis was 70 % in all patients with brain metastasis.•Response rate of brain metastasis was 60 % in group with untreated brain metastasis.•Pembrolizumab may have efficacy against brain metastasis of PD-L1 high NSCLC.

查看译文

关键词

Non-small cell lung cancer,Brain metastasis,High tumor PD-L1 expression,Pembrolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要